[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9Y_OPTItAaqygotK23vgtp5aFTTKmgHzH37BivyeJMM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":9,"topConditions":11,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Enanta Pharmaceuticals, Inc",[4],45,false,2,0,3450,[12,15,18,21,23,25,27,29],{"name":13,"count":14},"RSV Infection",13,{"name":16,"count":17},"NASH - Nonalcoholic Steatohepatitis",4,{"name":19,"count":20},"COVID-19",3,{"name":22,"count":20},"Respiratory Syncytial Virus (RSV)",{"name":24,"count":8},"Non-Alcoholic Steatohepatitis",{"name":26,"count":8},"NASH",{"name":28,"count":8},"Hepatitis C",{"name":30,"count":8},"Chronic HBV Infection",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT07540910","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults","2026-11","EDP-978",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07482657","A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus","2026-12","zelicapavir",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,86,109,231,285,310,328,356,374,392,410,437,455,481,499,525,543,570,588,646,676,722,768,804,834,864,890,934,960,982,1017,1039,1073,1108,1126,1144,1162,1180,1198,1216,1240,1258,1276,1300,1318],{"intervention":41,"totalTrials":8,"cells":51},{"EARLY_PHASE1":52,"PHASE1":54,"PHASE2":69,"PHASE3":80,"PHASE4":82,"NA":84},{"trials":53,"activeCount":9},[],{"trials":55,"activeCount":9},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"NCT06601192","A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults","COMPLETED",[44],"2025-02-02","2025-02-25","2024-07-15",72,[13,66],"QTc Interval",[41,41,68],"moxifloxacin",{"trials":70,"activeCount":79,"soonestReadout":40},[71],{"nctId":38,"briefTitle":39,"status":72,"phases":73,"primaryCompletion":40,"completion":40,"start":74,"enrollment":75,"conditions":76,"interventions":78},"NOT_YET_RECRUITING",[45],"2026-07",150,[13,77,22],"RSV",[41],1,{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[],{"intervention":36,"totalTrials":79,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":107},{"trials":89,"activeCount":9},[],{"trials":91,"activeCount":79,"soonestReadout":35},[92],{"nctId":33,"briefTitle":34,"status":93,"phases":94,"primaryCompletion":35,"completion":35,"start":95,"enrollment":96,"conditions":97,"interventions":100},"RECRUITING",[44],"2026-04-01",98,[98,99],"Chronic Inducible Urticaria","Chronic Spontaneous Urticaria",[36],{"trials":102,"activeCount":9},[],{"trials":104,"activeCount":9},[],{"trials":106,"activeCount":9},[],{"trials":108,"activeCount":9},[],{"intervention":110,"totalTrials":111,"cells":112},"EDP-938",10,{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":184,"PHASE3":225,"PHASE4":227,"NA":229},{"trials":114,"activeCount":9},[],{"trials":116,"activeCount":9},[117,129,141,152,161,170],{"nctId":118,"briefTitle":119,"status":59,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT03750383","Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects",[44],"2018-11-17","2018-12-13","2018-11-02",48,[13],[110,110,127,128],"Cyclosporine","Prednisone",{"nctId":130,"briefTitle":131,"status":59,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":64,"conditions":136,"interventions":137},"NCT03755778","Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects",[44],"2019-01-21","2019-01-27","2018-11-29",[13],[110,110,110,138,139,140],"Itraconazole","Rifampin","Quinidine",{"nctId":142,"briefTitle":143,"status":59,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT04871724","Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects",[44],"2021-03-30","2021-04-16","2021-03-12",24,[13],[110,151],"Fluconazole",{"nctId":153,"briefTitle":154,"status":59,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT04927793","Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects",[44],"2021-07-04","2021-05-28",8,[22],[110],{"nctId":162,"briefTitle":163,"status":59,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT03384823","A Study of EDP-938 in Healthy Subjects",[44],"2018-07-03","2017-12-07",90,[13],[110],{"nctId":171,"briefTitle":172,"status":59,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":179},"NCT04498741","Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects",[44],"2021-05-27","2021-06-01","2020-07-08",89,[13],[110,110,110,180,181,182,110,183],"Tacrolimus","Dabigatran","Rosuvastatin","Midazolam",{"trials":185,"activeCount":9},[186,195,204,215],{"nctId":187,"briefTitle":188,"status":59,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT05568706","A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.",[45],"2025-06-23","2022-11-29",186,[13],[110],{"nctId":196,"briefTitle":197,"status":59,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":203},"NCT04816721","A Study to Evaluate EDP 938 Regimens in Children With RSV",[45],"2024-08-19","2022-04-26",99,[22],[110],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT04633187","Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract","TERMINATED",[45],"2023-05-31","2021-07-07",9,[213],"Respiratory Syncytial Virus Infections",[110],{"nctId":216,"briefTitle":217,"status":59,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT04196101","A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects",[45],"2022-01-04","2020-01-22",82,[223],"Respiratory Syncytial Virus",[110],{"trials":226,"activeCount":9},[],{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[],{"intervention":232,"totalTrials":17,"cells":233},"EDP-235",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":267,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[238,249,258],{"nctId":239,"briefTitle":240,"status":59,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":247},"NCT05594602","Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.",[44],"2022-12-14","2022-12-30","2022-10-06",36,[19],[232,232,232,138,248,140],"Carbamazepine",{"nctId":250,"briefTitle":251,"status":59,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":64,"conditions":255,"interventions":257},"NCT05246878","A Study of EDP-235 in Healthy Subjects",[44],"2022-07-20","2022-01-28",[256],"SARS CoV 2 Infection",[232],{"nctId":259,"briefTitle":260,"status":59,"phases":261,"primaryCompletion":262,"completion":263,"start":244,"enrollment":148,"conditions":264,"interventions":265},"NCT05594615","Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects",[44],"2022-11-04","2022-11-18",[19],[232,183,182,266],"Caffeine",{"trials":268,"activeCount":9},[269],{"nctId":270,"briefTitle":271,"status":59,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT05616728","A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19",[45],"2023-02-08","2023-06-29","2022-11-10",231,[19],[232],{"trials":280,"activeCount":9},[],{"trials":282,"activeCount":9},[],{"trials":284,"activeCount":9},[],{"intervention":286,"totalTrials":79,"cells":287},"EDP-305 1.5 mg",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":289,"activeCount":9},[],{"trials":291,"activeCount":9},[],{"trials":293,"activeCount":9},[294],{"nctId":295,"briefTitle":296,"status":207,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":96,"conditions":301,"interventions":302},"NCT04378010","A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH",[45],"2021-10-04","2021-11-30","2020-01-27",[24],[286,303],"EDP-305 2 mg",{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[],{"trials":309,"activeCount":9},[],{"intervention":303,"totalTrials":79,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":313,"activeCount":9},[],{"trials":315,"activeCount":9},[],{"trials":317,"activeCount":9},[318],{"nctId":295,"briefTitle":296,"status":207,"phases":319,"primaryCompletion":298,"completion":299,"start":300,"enrollment":96,"conditions":320,"interventions":321},[45],[24],[286,303],{"trials":323,"activeCount":9},[],{"trials":325,"activeCount":9},[],{"trials":327,"activeCount":9},[],{"intervention":329,"totalTrials":79,"cells":330},"EDP-938 Dose 1",{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":332,"activeCount":9},[],{"trials":334,"activeCount":9},[],{"trials":336,"activeCount":9},[337],{"nctId":338,"briefTitle":339,"status":59,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":346},"NCT03691623","A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model",[45],"2019-09-30","2019-10-18","2018-10-15",179,[13],[329,347,348,349],"EDP-938 Dose 2","EDP-938 Dose 3","EDP-938 Dose 4",{"trials":351,"activeCount":9},[],{"trials":353,"activeCount":9},[],{"trials":355,"activeCount":9},[],{"intervention":347,"totalTrials":79,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":359,"activeCount":9},[],{"trials":361,"activeCount":9},[],{"trials":363,"activeCount":9},[364],{"nctId":338,"briefTitle":339,"status":59,"phases":365,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":366,"interventions":367},[45],[13],[329,347,348,349],{"trials":369,"activeCount":9},[],{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[],{"intervention":348,"totalTrials":79,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":377,"activeCount":9},[],{"trials":379,"activeCount":9},[],{"trials":381,"activeCount":9},[382],{"nctId":338,"briefTitle":339,"status":59,"phases":383,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":384,"interventions":385},[45],[13],[329,347,348,349],{"trials":387,"activeCount":9},[],{"trials":389,"activeCount":9},[],{"trials":391,"activeCount":9},[],{"intervention":349,"totalTrials":79,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":404,"PHASE4":406,"NA":408},{"trials":395,"activeCount":9},[],{"trials":397,"activeCount":9},[],{"trials":399,"activeCount":9},[400],{"nctId":338,"briefTitle":339,"status":59,"phases":401,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":402,"interventions":403},[45],[13],[329,347,348,349],{"trials":405,"activeCount":9},[],{"trials":407,"activeCount":9},[],{"trials":409,"activeCount":9},[],{"intervention":411,"totalTrials":79,"cells":412},"EDP-305 1 mg",{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":414,"activeCount":9},[],{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[419],{"nctId":420,"briefTitle":421,"status":59,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},"NCT03394924","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis",[45],"2019-12-19","2020-01-16","2017-12-27",68,[428],"Primary Biliary Cholangitis",[411,430],"EDP-305 2.5 mg",{"trials":432,"activeCount":9},[],{"trials":434,"activeCount":9},[],{"trials":436,"activeCount":9},[],{"intervention":430,"totalTrials":79,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":440,"activeCount":9},[],{"trials":442,"activeCount":9},[],{"trials":444,"activeCount":9},[445],{"nctId":420,"briefTitle":421,"status":59,"phases":446,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":447,"interventions":448},[45],[428],[411,430],{"trials":450,"activeCount":9},[],{"trials":452,"activeCount":9},[],{"trials":454,"activeCount":9},[],{"intervention":456,"totalTrials":79,"cells":457},"EDP-305 Dose 1",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":459,"activeCount":9},[],{"trials":461,"activeCount":9},[],{"trials":463,"activeCount":9},[464],{"nctId":465,"briefTitle":466,"status":59,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT03421431","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis",[45],"2019-06-14","2019-07-10","2018-04-25",134,[24],[456,474],"EDP-305 Dose 2",{"trials":476,"activeCount":9},[],{"trials":478,"activeCount":9},[],{"trials":480,"activeCount":9},[],{"intervention":474,"totalTrials":79,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":484,"activeCount":9},[],{"trials":486,"activeCount":9},[],{"trials":488,"activeCount":9},[489],{"nctId":465,"briefTitle":466,"status":59,"phases":490,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":491,"interventions":492},[45],[24],[456,474],{"trials":494,"activeCount":9},[],{"trials":496,"activeCount":9},[],{"trials":498,"activeCount":9},[],{"intervention":500,"totalTrials":79,"cells":501},"EDP-323 Dose Regimen 1",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":503,"activeCount":9},[],{"trials":505,"activeCount":9},[],{"trials":507,"activeCount":9},[508],{"nctId":509,"briefTitle":510,"status":59,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":517},"NCT06170242","A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model",[45],"2024-06-17","2024-07-12","2023-11-20",142,[13],[500,518],"EDP-323 Dose Regimen 2",{"trials":520,"activeCount":9},[],{"trials":522,"activeCount":9},[],{"trials":524,"activeCount":9},[],{"intervention":518,"totalTrials":79,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":9},[],{"trials":530,"activeCount":9},[],{"trials":532,"activeCount":9},[533],{"nctId":509,"briefTitle":510,"status":59,"phases":534,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":535,"interventions":536},[45],[13],[500,518],{"trials":538,"activeCount":9},[],{"trials":540,"activeCount":9},[],{"trials":542,"activeCount":9},[],{"intervention":544,"totalTrials":79,"cells":545},"EDP-420 \u002F Duration of Treatment - 3 days",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":547,"activeCount":9},[],{"trials":549,"activeCount":9},[],{"trials":551,"activeCount":9},[552],{"nctId":553,"briefTitle":554,"status":555,"phases":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT00270517","Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia","UNKNOWN",[45],"2007-07","2005-12",250,[561],"Community Acquired Pneumonia",[544,563],"Telithromycin \u002F Duration of Treatment - 7 days",{"trials":565,"activeCount":9},[],{"trials":567,"activeCount":9},[],{"trials":569,"activeCount":9},[],{"intervention":563,"totalTrials":79,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":573,"activeCount":9},[],{"trials":575,"activeCount":9},[],{"trials":577,"activeCount":9},[578],{"nctId":553,"briefTitle":554,"status":555,"phases":579,"completion":557,"start":558,"enrollment":559,"conditions":580,"interventions":581},[45],[561],[544,563],{"trials":583,"activeCount":9},[],{"trials":585,"activeCount":9},[],{"trials":587,"activeCount":9},[],{"intervention":140,"totalTrials":589,"cells":590},5,{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":592,"activeCount":9},[],{"trials":594,"activeCount":9},[595,608,612,624,628],{"nctId":596,"briefTitle":597,"status":59,"phases":598,"primaryCompletion":599,"completion":600,"start":601,"enrollment":124,"conditions":602,"interventions":604},"NCT06847464","A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.",[44],"2025-05-24","2025-06-01","2025-01-27",[13,603],"Drug Drug Interaction (DDI)",[605,138,605,606,605,140,605,607],"EDP-323","carbamazepine","fluconazole",{"nctId":239,"briefTitle":240,"status":59,"phases":609,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":610,"interventions":611},[44],[19],[232,232,232,138,248,140],{"nctId":613,"briefTitle":614,"status":59,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":64,"conditions":619,"interventions":621},"NCT04783753","Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects",[44],"2021-06-28","2021-07-09","2020-11-05",[620],"Hepatitis B",[622,622,622,138,623,140],"EDP-514","Carbamazepin",{"nctId":130,"briefTitle":131,"status":59,"phases":625,"primaryCompletion":133,"completion":134,"start":135,"enrollment":64,"conditions":626,"interventions":627},[44],[13],[110,110,110,138,139,140],{"nctId":629,"briefTitle":630,"status":59,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":124,"conditions":635,"interventions":636},"NCT03610945","Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers",[44],"2018-08-15","2018-08-21","2018-07-19",[16],[151,140,637,637],"EDP-305",{"trials":639,"activeCount":9},[],{"trials":641,"activeCount":9},[],{"trials":643,"activeCount":9},[],{"trials":645,"activeCount":9},[],{"intervention":138,"totalTrials":17,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":649,"activeCount":9},[],{"trials":651,"activeCount":9},[652,656,660,664],{"nctId":596,"briefTitle":597,"status":59,"phases":653,"primaryCompletion":599,"completion":600,"start":601,"enrollment":124,"conditions":654,"interventions":655},[44],[13,603],[605,138,605,606,605,140,605,607],{"nctId":239,"briefTitle":240,"status":59,"phases":657,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":658,"interventions":659},[44],[19],[232,232,232,138,248,140],{"nctId":613,"briefTitle":614,"status":59,"phases":661,"primaryCompletion":616,"completion":617,"start":618,"enrollment":64,"conditions":662,"interventions":663},[44],[620],[622,622,622,138,623,140],{"nctId":130,"briefTitle":131,"status":59,"phases":665,"primaryCompletion":133,"completion":134,"start":135,"enrollment":64,"conditions":666,"interventions":667},[44],[13],[110,110,110,138,139,140],{"trials":669,"activeCount":9},[],{"trials":671,"activeCount":9},[],{"trials":673,"activeCount":9},[],{"trials":675,"activeCount":9},[],{"intervention":622,"totalTrials":17,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":714,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":679,"activeCount":9},[],{"trials":681,"activeCount":9},[682,686,697,706],{"nctId":613,"briefTitle":614,"status":59,"phases":683,"primaryCompletion":616,"completion":617,"start":618,"enrollment":64,"conditions":684,"interventions":685},[44],[620],[622,622,622,138,623,140],{"nctId":687,"briefTitle":688,"status":207,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT04971512","A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.",[44],"2021-12-20","2021-08-02",26,[694],"Chronic Hepatitis B Virus Infection",[696,696,622],"EDP-721",{"nctId":698,"briefTitle":699,"status":59,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT04470388","A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment",[44],"2021-08-30","2020-09-09",25,[30],[622],{"nctId":707,"briefTitle":708,"status":59,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":201,"conditions":712,"interventions":713},"NCT04008004","A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)",[44],"2021-07-14","2019-06-26",[30],[622],{"trials":715,"activeCount":9},[],{"trials":717,"activeCount":9},[],{"trials":719,"activeCount":9},[],{"trials":721,"activeCount":9},[],{"intervention":637,"totalTrials":17,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":766},{"trials":725,"activeCount":9},[],{"trials":727,"activeCount":9},[728,736,740,751],{"nctId":729,"briefTitle":730,"status":59,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":158,"conditions":734,"interventions":735},"NCT03748628","Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects",[44],"2018-10-13","2018-10-05",[16],[637],{"nctId":629,"briefTitle":630,"status":59,"phases":737,"primaryCompletion":632,"completion":633,"start":634,"enrollment":124,"conditions":738,"interventions":739},[44],[16],[151,140,637,637],{"nctId":741,"briefTitle":742,"status":59,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT03783897","A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects",[44],"2019-06-04","2019-06-18","2018-11-27",43,[16],[637,750],"Oral Contraceptive",{"nctId":752,"briefTitle":753,"status":59,"phases":754,"primaryCompletion":755,"completion":756,"start":757,"enrollment":148,"conditions":758,"interventions":759},"NCT03187496","Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.",[44],"2017-06-01","2017-06-14","2017-05-11",[26],[183,266,182,637],{"trials":761,"activeCount":9},[],{"trials":763,"activeCount":9},[],{"trials":765,"activeCount":9},[],{"trials":767,"activeCount":9},[],{"intervention":183,"totalTrials":17,"cells":769},{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":771,"activeCount":9},[],{"trials":773,"activeCount":9},[774,784,788,792],{"nctId":775,"briefTitle":776,"status":59,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":148,"conditions":781,"interventions":783},"NCT06917508","A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",[44],"2025-06-06","2025-06-13","2025-03-13",[13,782],"Drug Drug Interaction",[605,183,266,182],{"nctId":259,"briefTitle":260,"status":59,"phases":785,"primaryCompletion":262,"completion":263,"start":244,"enrollment":148,"conditions":786,"interventions":787},[44],[19],[232,183,182,266],{"nctId":752,"briefTitle":753,"status":59,"phases":789,"primaryCompletion":755,"completion":756,"start":757,"enrollment":148,"conditions":790,"interventions":791},[44],[26],[183,266,182,637],{"nctId":171,"briefTitle":172,"status":59,"phases":793,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":794,"interventions":795},[44],[13],[110,110,110,180,181,182,110,183],{"trials":797,"activeCount":9},[],{"trials":799,"activeCount":9},[],{"trials":801,"activeCount":9},[],{"trials":803,"activeCount":9},[],{"intervention":182,"totalTrials":17,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":832},{"trials":807,"activeCount":9},[],{"trials":809,"activeCount":9},[810,814,818,822],{"nctId":775,"briefTitle":776,"status":59,"phases":811,"primaryCompletion":778,"completion":779,"start":780,"enrollment":148,"conditions":812,"interventions":813},[44],[13,782],[605,183,266,182],{"nctId":259,"briefTitle":260,"status":59,"phases":815,"primaryCompletion":262,"completion":263,"start":244,"enrollment":148,"conditions":816,"interventions":817},[44],[19],[232,183,182,266],{"nctId":752,"briefTitle":753,"status":59,"phases":819,"primaryCompletion":755,"completion":756,"start":757,"enrollment":148,"conditions":820,"interventions":821},[44],[26],[183,266,182,637],{"nctId":171,"briefTitle":172,"status":59,"phases":823,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":824,"interventions":825},[44],[13],[110,110,110,180,181,182,110,183],{"trials":827,"activeCount":9},[],{"trials":829,"activeCount":9},[],{"trials":831,"activeCount":9},[],{"trials":833,"activeCount":9},[],{"intervention":605,"totalTrials":20,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":837,"activeCount":9},[],{"trials":839,"activeCount":9},[840,844,848],{"nctId":596,"briefTitle":597,"status":59,"phases":841,"primaryCompletion":599,"completion":600,"start":601,"enrollment":124,"conditions":842,"interventions":843},[44],[13,603],[605,138,605,606,605,140,605,607],{"nctId":775,"briefTitle":776,"status":59,"phases":845,"primaryCompletion":778,"completion":779,"start":780,"enrollment":148,"conditions":846,"interventions":847},[44],[13,782],[605,183,266,182],{"nctId":849,"briefTitle":850,"status":59,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":221,"conditions":854,"interventions":855},"NCT05587478","A Study of EDP-323 in Healthy Subjects",[44],"2023-03-29","2022-09-29",[13],[605],{"trials":857,"activeCount":9},[],{"trials":859,"activeCount":9},[],{"trials":861,"activeCount":9},[],{"trials":863,"activeCount":9},[],{"intervention":151,"totalTrials":20,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":867,"activeCount":9},[],{"trials":869,"activeCount":9},[870,874,878],{"nctId":596,"briefTitle":597,"status":59,"phases":871,"primaryCompletion":599,"completion":600,"start":601,"enrollment":124,"conditions":872,"interventions":873},[44],[13,603],[605,138,605,606,605,140,605,607],{"nctId":629,"briefTitle":630,"status":59,"phases":875,"primaryCompletion":632,"completion":633,"start":634,"enrollment":124,"conditions":876,"interventions":877},[44],[16],[151,140,637,637],{"nctId":142,"briefTitle":143,"status":59,"phases":879,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":880,"interventions":881},[44],[13],[110,151],{"trials":883,"activeCount":9},[],{"trials":885,"activeCount":9},[],{"trials":887,"activeCount":9},[],{"trials":889,"activeCount":9},[],{"intervention":891,"totalTrials":20,"cells":892},"EDP 305",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":894,"activeCount":9},[],{"trials":896,"activeCount":9},[897,907,916],{"nctId":898,"briefTitle":899,"status":59,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":906},"NCT02918929","A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD",[44],"2017-06","2016-09",146,[905],"Presumptive NAFLD",[891],{"nctId":908,"briefTitle":909,"status":59,"phases":910,"primaryCompletion":911,"completion":912,"start":756,"enrollment":913,"conditions":914,"interventions":915},"NCT03207425","A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers",[44],"2017-09-16","2017-09-19",29,[26],[891],{"nctId":917,"briefTitle":918,"status":59,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":124,"conditions":923,"interventions":924},"NCT03213145","Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers",[44],"2017-08-10","2017-09-07","2017-07-11",[16],[925,139,891],"intraconazole",{"trials":927,"activeCount":9},[],{"trials":929,"activeCount":9},[],{"trials":931,"activeCount":9},[],{"trials":933,"activeCount":9},[],{"intervention":266,"totalTrials":20,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":937,"activeCount":9},[],{"trials":939,"activeCount":9},[940,944,948],{"nctId":775,"briefTitle":776,"status":59,"phases":941,"primaryCompletion":778,"completion":779,"start":780,"enrollment":148,"conditions":942,"interventions":943},[44],[13,782],[605,183,266,182],{"nctId":259,"briefTitle":260,"status":59,"phases":945,"primaryCompletion":262,"completion":263,"start":244,"enrollment":148,"conditions":946,"interventions":947},[44],[19],[232,183,182,266],{"nctId":752,"briefTitle":753,"status":59,"phases":949,"primaryCompletion":755,"completion":756,"start":757,"enrollment":148,"conditions":950,"interventions":951},[44],[26],[183,266,182,637],{"trials":953,"activeCount":9},[],{"trials":955,"activeCount":9},[],{"trials":957,"activeCount":9},[],{"trials":959,"activeCount":9},[],{"intervention":606,"totalTrials":8,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":963,"activeCount":9},[],{"trials":965,"activeCount":9},[966,970],{"nctId":596,"briefTitle":597,"status":59,"phases":967,"primaryCompletion":599,"completion":600,"start":601,"enrollment":124,"conditions":968,"interventions":969},[44],[13,603],[605,138,605,606,605,140,605,607],{"nctId":239,"briefTitle":240,"status":59,"phases":971,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":972,"interventions":973},[44],[19],[232,232,232,138,248,140],{"trials":975,"activeCount":9},[],{"trials":977,"activeCount":9},[],{"trials":979,"activeCount":9},[],{"trials":981,"activeCount":9},[],{"intervention":983,"totalTrials":8,"cells":984},"EDP-788",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":986,"activeCount":9},[],{"trials":988,"activeCount":9},[989,999],{"nctId":990,"briefTitle":991,"status":207,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT02255968","Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788",[44],"2014-10","2014-08",16,[997],"Healthy",[983],{"nctId":1000,"briefTitle":1001,"status":59,"phases":1002,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1008},"NCT01999725","Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788",[44],"2014-09","2014-01",80,[1007],"Safety in Normal Volunteers",[983],{"trials":1010,"activeCount":9},[],{"trials":1012,"activeCount":9},[],{"trials":1014,"activeCount":9},[],{"trials":1016,"activeCount":9},[],{"intervention":139,"totalTrials":8,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1020,"activeCount":9},[],{"trials":1022,"activeCount":9},[1023,1027],{"nctId":130,"briefTitle":131,"status":59,"phases":1024,"primaryCompletion":133,"completion":134,"start":135,"enrollment":64,"conditions":1025,"interventions":1026},[44],[13],[110,110,110,138,139,140],{"nctId":917,"briefTitle":918,"status":59,"phases":1028,"primaryCompletion":920,"completion":921,"start":922,"enrollment":124,"conditions":1029,"interventions":1030},[44],[16],[925,139,891],{"trials":1032,"activeCount":9},[],{"trials":1034,"activeCount":9},[],{"trials":1036,"activeCount":9},[],{"trials":1038,"activeCount":9},[],{"intervention":1040,"totalTrials":8,"cells":1041},"EDP239",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1043,"activeCount":9},[],{"trials":1045,"activeCount":9},[1046,1056],{"nctId":1047,"briefTitle":1048,"status":59,"phases":1049,"primaryCompletion":1050,"completion":1050,"start":994,"enrollment":1051,"conditions":1052,"interventions":1054},"NCT02173574","Two-way Interaction Between Alisporivir and EDP239",[44],"2014-11",42,[1053],"Hepatitis C Virus",[1055,1040],"DEB025",{"nctId":1057,"briefTitle":1058,"status":59,"phases":1059,"primaryCompletion":1050,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1064},"NCT01856426","Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects",[44],"2015-10","2013-06",28,[28],[1040],{"trials":1066,"activeCount":9},[],{"trials":1068,"activeCount":9},[],{"trials":1070,"activeCount":9},[],{"trials":1072,"activeCount":9},[],{"intervention":1074,"totalTrials":8,"cells":1075},"EDP-322",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1077,"activeCount":9},[],{"trials":1079,"activeCount":9},[1080,1091],{"nctId":1081,"briefTitle":1082,"status":59,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1090},"NCT00990145","Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers",[44],"2009-03","2009-09","2008-11",52,[1089],"MRSA, SSTI",[1074],{"nctId":1092,"briefTitle":1093,"status":59,"phases":1094,"enrollment":1095,"conditions":1096,"interventions":1099},"NCT00989872","Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers",[44],67,[1097,1098],"Skin and Soft Tissue Infections","Methicillin-resistant Staphylococcus Aureus",[1074],{"trials":1101,"activeCount":9},[],{"trials":1103,"activeCount":9},[],{"trials":1105,"activeCount":9},[],{"trials":1107,"activeCount":9},[],{"intervention":623,"totalTrials":79,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1111,"activeCount":9},[],{"trials":1113,"activeCount":9},[1114],{"nctId":613,"briefTitle":614,"status":59,"phases":1115,"primaryCompletion":616,"completion":617,"start":618,"enrollment":64,"conditions":1116,"interventions":1117},[44],[620],[622,622,622,138,623,140],{"trials":1119,"activeCount":9},[],{"trials":1121,"activeCount":9},[],{"trials":1123,"activeCount":9},[],{"trials":1125,"activeCount":9},[],{"intervention":127,"totalTrials":79,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1129,"activeCount":9},[],{"trials":1131,"activeCount":9},[1132],{"nctId":118,"briefTitle":119,"status":59,"phases":1133,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1134,"interventions":1135},[44],[13],[110,110,127,128],{"trials":1137,"activeCount":9},[],{"trials":1139,"activeCount":9},[],{"trials":1141,"activeCount":9},[],{"trials":1143,"activeCount":9},[],{"intervention":128,"totalTrials":79,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1147,"activeCount":9},[],{"trials":1149,"activeCount":9},[1150],{"nctId":118,"briefTitle":119,"status":59,"phases":1151,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1152,"interventions":1153},[44],[13],[110,110,127,128],{"trials":1155,"activeCount":9},[],{"trials":1157,"activeCount":9},[],{"trials":1159,"activeCount":9},[],{"trials":1161,"activeCount":9},[],{"intervention":696,"totalTrials":79,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1165,"activeCount":9},[],{"trials":1167,"activeCount":9},[1168],{"nctId":687,"briefTitle":688,"status":207,"phases":1169,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":1170,"interventions":1171},[44],[694],[696,696,622],{"trials":1173,"activeCount":9},[],{"trials":1175,"activeCount":9},[],{"trials":1177,"activeCount":9},[],{"trials":1179,"activeCount":9},[],{"intervention":1055,"totalTrials":79,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1183,"activeCount":9},[],{"trials":1185,"activeCount":9},[1186],{"nctId":1047,"briefTitle":1048,"status":59,"phases":1187,"primaryCompletion":1050,"completion":1050,"start":994,"enrollment":1051,"conditions":1188,"interventions":1189},[44],[1053],[1055,1040],{"trials":1191,"activeCount":9},[],{"trials":1193,"activeCount":9},[],{"trials":1195,"activeCount":9},[],{"trials":1197,"activeCount":9},[],{"intervention":750,"totalTrials":79,"cells":1199},{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1201,"activeCount":9},[],{"trials":1203,"activeCount":9},[1204],{"nctId":741,"briefTitle":742,"status":59,"phases":1205,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":1206,"interventions":1207},[44],[16],[637,750],{"trials":1209,"activeCount":9},[],{"trials":1211,"activeCount":9},[],{"trials":1213,"activeCount":9},[],{"trials":1215,"activeCount":9},[],{"intervention":1217,"totalTrials":79,"cells":1218},"EDP-494",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1220,"activeCount":9},[],{"trials":1222,"activeCount":9},[1223],{"nctId":1224,"briefTitle":1225,"status":59,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT02652377","EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients",[44],"2016-12-27","2016-01-10",100,[28],[1217],{"trials":1233,"activeCount":9},[],{"trials":1235,"activeCount":9},[],{"trials":1237,"activeCount":9},[],{"trials":1239,"activeCount":9},[],{"intervention":180,"totalTrials":79,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":9},[],{"trials":1245,"activeCount":9},[1246],{"nctId":171,"briefTitle":172,"status":59,"phases":1247,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":1248,"interventions":1249},[44],[13],[110,110,110,180,181,182,110,183],{"trials":1251,"activeCount":9},[],{"trials":1253,"activeCount":9},[],{"trials":1255,"activeCount":9},[],{"trials":1257,"activeCount":9},[],{"intervention":181,"totalTrials":79,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":9},[],{"trials":1263,"activeCount":9},[1264],{"nctId":171,"briefTitle":172,"status":59,"phases":1265,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":1266,"interventions":1267},[44],[13],[110,110,110,180,181,182,110,183],{"trials":1269,"activeCount":9},[],{"trials":1271,"activeCount":9},[],{"trials":1273,"activeCount":9},[],{"trials":1275,"activeCount":9},[],{"intervention":1277,"totalTrials":79,"cells":1278},"EDP-297",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1280,"activeCount":9},[],{"trials":1282,"activeCount":9},[1283],{"nctId":1284,"briefTitle":1285,"status":59,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":221,"conditions":1289,"interventions":1291},"NCT04559126","A Study of EDP-297 in Healthy Subjects",[44],"2021-06-21","2020-09-08",[1290],"NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis",[1277],{"trials":1293,"activeCount":9},[],{"trials":1295,"activeCount":9},[],{"trials":1297,"activeCount":9},[],{"trials":1299,"activeCount":9},[],{"intervention":68,"totalTrials":79,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1310,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1303,"activeCount":9},[],{"trials":1305,"activeCount":9},[1306],{"nctId":57,"briefTitle":58,"status":59,"phases":1307,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":1308,"interventions":1309},[44],[13,66],[41,41,68],{"trials":1311,"activeCount":9},[],{"trials":1313,"activeCount":9},[],{"trials":1315,"activeCount":9},[],{"trials":1317,"activeCount":9},[],{"intervention":925,"totalTrials":79,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1321,"activeCount":9},[],{"trials":1323,"activeCount":9},[1324],{"nctId":917,"briefTitle":918,"status":59,"phases":1325,"primaryCompletion":920,"completion":921,"start":922,"enrollment":124,"conditions":1326,"interventions":1327},[44],[16],[925,139,891],{"trials":1329,"activeCount":9},[],{"trials":1331,"activeCount":9},[],{"trials":1333,"activeCount":9},[],{"trials":1335,"activeCount":9},[]]